title: Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
abstract: The relationship between plasma protease inhibitor (PI) trough concentrations and hyperlipidemic effects were evaluated retrospectively using data from 2 pilot clinical trials of a double-boosted PI regimen (saquinavir/lopinavir/ritonavir) in 25 HIV patients. The patients' median age was 39 years (range, 25-60). At baseline, PI-naive patients had a median viral load of 53 500 copies/mL and median CD4 of 296 cells/mm(3), while PI-experienced patients had 37 750 copies/mL and 214 cells/mm(3). Plasma PI trough concentrations of saquinavir, lopinavir, and ritonavir at week 12 were 520, 4482, and 153 ng/mL, respectively. At week 12, median fasting lipids increased significantly from baseline: total cholesterol increased from 165 to 189 mg/dL (P = .0005) and the triglyceride increased from 113 to 159 mg/dL (P = .001). There were no associations between PI trough concentrations at week 12 and the percent total cholesterol change at week 12. No associations were found between PI trough concentrations and lipid changes in HIV patients on a double-boosted PI regimen (saquinavir/lopinavir/ritonavir). Factors other than systemic exposure to PIs (such as host or genetic factors) may modulate the hyperlipidemic effect of PIs.
authors.affiliation: Tufts Medical Center, Division of Geographic Medicine and Infectious Disease, 800 Washington St, Box 41, Boston, MA 02111, USA. mrhee@tuftsmedicalcenter.org
authors.forename: Martin S
authors.initials: MS
authors.lastname: Rhee
authors.forename: James A
authors.initials: JA
authors.lastname: Hellinger
authors.forename: Sandy
authors.initials: S
authors.lastname: Sheble-Hall
authors.forename: Calvin J
authors.initials: CJ
authors.lastname: Cohen
authors.forename: David J
authors.initials: DJ
authors.lastname: Greenblatt
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000097:blood*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis; D008055:Lipids / Q000096:biosynthesis*; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011744:Pyrimidinones / Q000008:administration & dosage / Q000097:blood; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000097:blood; D019258:Saquinavir / Q000008:administration & dosage / Q000097:blood
chemical_list: D017320:HIV Protease Inhibitors; D008055:Lipids; D011744:Pyrimidinones; D061466:Lopinavir; D019258:Saquinavir; D019438:Ritonavir